WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 17, 145-168. Review Article ISSN 2277–7105

BIOAVAILABILITY IN DRUG DESIGN AND DEVELOPMENT: A COMPREHENSIVE REVIEW

Arati Bhandare* and Kaveri M. Nannor

(Department of Pharmaceutical Quality Assurance)
Pravara Rural Education Society College of Pharmacy (Womens), Chincholi Tal: Sinnar Dist: Nashik, Pincode: 422102.

Article Received on
05 July 2024,
Revised on 25 July 2024,
Accepted on 15 August 2024
DOI: 10.20959/wjpr202417-33652

***Corresponding Author**
Arati Bhandare
(Department of Pharmaceutical Quality Assurance) Pravara Rural Education Society College of Pharmacy (Womens), Chincholi Tal: Sinnar Dist: Nashik, Pincode: 422102.

ABSTRACT

Bioavailability is a critical factor in drug design and development, influencing the therapeutic efficacy and safety profile of pharmaceutical compounds. This review article explores the multifaceted role of bioavailability in the development of new drugs, highlighting its significance in the pharmacokinetic and pharmacodynamic phases. Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation and is available at the site of action. Factors such as solubility, permeability, and first-pass metabolism significantly affect bioavailability, thereby determining the dosage, administration route, and overall effectiveness of a drug. The review begins with a comprehensive overview of bioavailability, including its definition, measurement techniques, and regulatory considerations. It then delves into the physiological and biochemical mechanisms that influence bioavailability, such as gastrointestinal absorption, hepatic metabolism, and drug transporters. Various strategies to enhance bioavailability are discussed, including the use of prodrugs, nanoformulations, and advanced drug delivery systems like liposomes and hydrogels. Preclinical and clinical studies underscore the importance of bioavailability in drug development. In preclinical phases, animal models and in vitro assays are employed to predict human bioavailability and optimize drug candidates. Clinical trials further elucidate the relationship between bioavailability and therapeutic outcomes, guiding dosage adjustments and formulation improvements. Several case studies are presented to illustrate successful applications of bioavailability enhancement techniques

in marketed drugs. The review also addresses the challenges and limitations in achieving optimal bioavailability, such as interindividual variability and the complexity of biological barriers. Emerging trends and future directions in bioavailability research, including the development of predictive models and personalized medicine approaches, are explored. This article underscores the indispensable role of bioavailability in drug design and development, advocating for continued research and innovation to improve drug efficacy and patient outcomes.

KEYWORDS: Bioavailability, Pharmacokinetics, Drug Design, Pharmacodynamics, Drug Delivery Systems, Preclinical Studies, Bioavailability Enhancement.

INTRODUCTION

Background

Introducing Bioavailability and Its Relevance to Drug Design and Development

Bioavailability is a fundamental concept in pharmacology and drug development, referring to the proportion of an administered drug that reaches the systemic circulation and is available at the target site to exert its therapeutic effect. This concept is crucial as it directly impacts a drug's efficacy, safety, and overall therapeutic outcome. Bioavailability can be influenced by several factors, including the drug's formulation, its route of administration, and the physiological and biochemical barriers within the body. For instance, oral medications must pass through the gastrointestinal tract, where they may be subjected to enzymatic degradation, first-pass metabolism in the liver, and variable absorption rates across different regions of the digestive system. These factors can significantly alter the amount of active drug that ultimately reaches systemic circulation.[24,30]

In drug design and development, understanding and optimizing bioavailability are essential to ensure that drugs achieve their intended therapeutic effects. A drug with poor bioavailability may require higher doses or more frequent administration, which can lead to increased side effects and reduced patient compliance. Therefore, pharmaceutical scientists employ various strategies to enhance bioavailability, including modifications in drug formulation, such as the use of nanoparticles, liposomes, or prodrugs, which can improve solubility and permeability.[36,26] Additionally, bioavailability plays a pivotal role in determining the appropriate dosing regimen during clinical trials and in the final drug product. Accurate prediction of bioavailability in preclinical studies helps in the selection of drug candidates that are likely to perform well in human trials. Innovations in drug delivery systems and

advances in predictive modeling are continually improving our ability to optimize bioavailability and enhance the therapeutic efficacy of new drugs. In summary, bioavailability is a critical parameter in drug design and development, influencing both the clinical success of new drugs and their overall safety profiles. A thorough understanding of bioavailability allows for the development of more effective and patient-friendly medications.[28,8,52]

Importance of Bioavailability in Pharmacology and Drug Development

Bioavailability is a pivotal factor in pharmacology and drug development due to its direct impact on a drug's therapeutic efficacy, safety, and overall effectiveness. It refers to the fraction of an administered dose of a drug that reaches systemic circulation in an active form and is available at the site of action. The importance of bioavailability can be understood through several key aspects:

1. **Therapeutic efficacy:** The primary goal of drug therapy is to achieve a therapeutic concentration of the drug at its target site. A drug with low bioavailability may not reach adequate levels in the bloodstream or at the site of action, leading to reduced efficacy. For example, a drug with poor gastrointestinal absorption might not achieve sufficient plasma levels to be effective, requiring dose escalation which may not always be feasible or safe.

2. **Dose optimization:** Accurate knowledge of a drug's bioavailability is essential for determining appropriate dosing regimens. Drugs with high bioavailability may require lower doses to achieve therapeutic effects, whereas those with low bioavailability might need higher doses or frequent administration. Inaccurate dosing can lead to suboptimal therapeutic outcomes or increased risk of side effects.

3. **Safety and Side effects:** Bioavailability affects the drug's distribution and metabolism, influencing its safety profile. Drugs with high bioavailability and poor metabolic stability may accumulate to toxic levels, leading to adverse effects. Conversely, drugs with low bioavailability might require higher doses to achieve efficacy, potentially increasing the risk of side effects due to higher doses.

4. **Drug Formulation and Delivery:** The formulation of a drug can significantly impact its bioavailability. Advanced drug delivery systems, such as controlled-release formulations, nanoparticles, and liposomes, are designed to enhance bioavailability by improving solubility, stability, and permeability. Understanding bioavailability is crucial for developing these technologies and ensuring they provide the intended therapeutic benefit.

5. **Clinical Trials and Drug approval:** During drug development, bioavailability studies are essential for designing clinical trials and interpreting their results. Regulatory agencies, such as the FDA and EMA, require detailed bioavailability data to assess a drug's safety and efficacy before approval. Bioavailability assessments guide dose selection, formulation adjustments, and labeling recommendations.

6. **Personalized medicine:** Variability in bioavailability among individuals due to genetic differences, age, or health conditions can affect drug response. Personalized medicine approaches take these factors into account to optimize dosing and improve therapeutic outcomes. Understanding bioavailability helps in tailoring treatments to individual needs, enhancing the precision and effectiveness of drug therapy.

The bioavailability is critical in pharmacology and drug development as it influences drug efficacy, safety, dosing, and overall therapeutic success. A thorough understanding of bioavailability helps in designing effective drug formulations, optimizing clinical trials, and advancing personalized medicine.

The objective of this review is to thoroughly explore the role of bioavailability in drug design and development, emphasizing its impact on drug efficacy, safety, and formulation strategies. The review aims to define bioavailability, examine the physiological and biochemical mechanisms affecting it, and discuss various enhancement techniques such as advanced drug delivery systems and formulation strategies. It will also address how bioavailability influences preclinical and clinical drug development processes, highlight common challenges and limitations, and explore emerging trends and future research directions. By providing a comprehensive overview, this review seeks to enhance understanding of bioavailability's critical role in optimizing drug development and therapeutic outcomes.[1,2,3,4]

Literature review

Definition and Importance of bioavailability

Definitions and Terminologies

Bioavailability is defined as the proportion of an administered drug that reaches the systemic circulation in an active form and is available for therapeutic effect. This concept is central to pharmacokinetics, the branch of pharmacology that deals with the absorption, distribution, metabolism, and excretion of drugs. The term "bioavailability" is often used interchangeably with "absolute bioavailability" when referring to the fraction of an oral dose that reaches the

systemic circulation compared to intravenous administration, which serves as the reference standard.[5,6]



Figure No. 1: Drug concentration compared to time of Intravenous and Oral Routes and How this is used to establish the bioavailability of a drug.

Key terminologies related to bioavailability include

- **Absorption:** The process by which a drug moves from its site of administration into the bloodstream. Factors influencing absorption include drug formulation, gastrointestinal pH, and presence of food.
- **First-Pass metabolism:** The reduction in drug concentration that occurs when the drug is metabolized by the liver before reaching systemic circulation. This is particularly relevant for orally administered drugs.
- **Permeability:** The ability of a drug to cross biological membranes, such as the intestinal wall, which affects how much of the drug reaches systemic circulation.[7,8]

Significance in Pharmacology and Drug development

Bioavailability is crucial in Pharmacology and Drug development for several reasons

1. **Therapeutic efficacy:** The therapeutic efficacy of a drug is directly related to its bioavailability. A drug with high bioavailability can achieve effective plasma concentrations at lower doses, potentially improving therapeutic outcomes and reducing the risk of side effects. Conversely, drugs with low bioavailability may require higher doses to achieve the desired therapeutic effect, which can lead to increased side effects and reduced patient adherence.

2. **Dose optimization:** Accurate knowledge of a drug's bioavailability allows for appropriate dosing regimens. This is essential for designing dosing schedules that maximize therapeutic benefits while minimizing adverse effects. For example, drugs with low bioavailability might need to be administered in higher doses or with specific formulations to enhance absorption.

3. **Drug formulation:** Understanding bioavailability is fundamental in drug formulation and development. Techniques such as the use of nanoparticles, prodrugs, and novel drug delivery systems are employed to enhance bioavailability and improve the performance of drugs. This is particularly important for drugs with poor solubility or stability.

4. **Regulatory considerations:** Regulatory agencies, such as the FDA and EMA, require detailed bioavailability data to approve new drugs. These data help determine the appropriate dosing, labeling, and usage recommendations. Bioavailability studies are critical in the development of generic drugs and the evaluation of drug-drug interactions.

5. **Personalized medicine:** Bioavailability also plays a role in personalized medicine. Variations in bioavailability among individuals due to genetic differences, age, or health conditions can influence drug efficacy and safety. Tailoring treatments based on bioavailability can lead to more effective and individualized therapeutic strategies.[9,10,11]

Mechanisms influencing bioavailability

Physiological mechanisms

1. **Absorption:** Absorption is the process by which a drug moves from its site of administration into the bloodstream. The rate and extent of absorption can be influenced by several factors, including the drug’s formulation, the presence of food in the gastrointestinal tract, and the drug’s ability to dissolve in the gastrointestinal fluids. Drugs that are rapidly absorbed can reach peak plasma concentrations more quickly, whereas those with poor absorption may require alternative formulations or delivery methods to improve their bioavailability.

2. **Distribution:** After absorption, the drug is distributed throughout the body. Distribution depends on factors such as blood flow to various tissues, the drug's affinity for tissues, and the ability to cross biological membranes. Drugs that bind strongly to plasma proteins may have reduced free drug concentrations available to exert therapeutic effects.

Additionally, the drug's ability to cross the blood-brain barrier or placental barrier can impact its efficacy and safety.

3. **Metabolism:** Metabolism, primarily occurring in the liver, involves the chemical modification of the drug by enzymes. First-pass metabolism refers to the reduction in drug concentration that occurs when the drug is metabolized by the liver before reaching systemic circulation. Drugs with significant first-pass metabolism may have low oral bioavailability, necessitating alternative routes of administration or formulation strategies to bypass this effect.

4. **Excretion:** The elimination of drugs from the body primarily occurs through the kidneys (urine) or liver (bile). The rate of excretion can affect drug levels in the bloodstream and, consequently, the drug's efficacy and safety. Factors such as renal or hepatic impairment can significantly alter drug excretion and bioavailability, leading to the need for dose adjustments or alternative therapies.[12,13,14,15]



Figure No. 2: The bioavailability of drugs-the current state of knowledge.

Biochemical mechanisms

1. **Drug solubility:** Solubility refers to the ability of a drug to dissolve in a given solvent, such as gastrointestinal fluids. Drugs with poor solubility may not be adequately absorbed, leading to reduced bioavailability. Techniques to improve solubility include the use of solubilizing agents, nanoparticle formulations, and solid dispersions.

2. **Permeability:** Permeability is the ability of a drug to cross biological membranes, such as the intestinal wall. Drugs with high permeability can efficiently pass through cellular barriers and enter systemic circulation. The permeability of a drug can be influenced by

its molecular size, lipophilicity, and the presence of efflux pumps such as P-glycoprotein, which can actively transport drugs out of cells and reduce their bioavailability.[16,17]

Methods to enhance bioavailability

Enhancing bioavailability is crucial for improving the efficacy and safety of pharmaceuticals. Various drug formulation techniques and advanced delivery systems are employed to address challenges related to drug solubility, permeability, and stability. Below is a detailed overview of these methods.

Drug formulation techniques

1. **Nanoparticle formulations:** Nanoparticles are engineered to improve the solubility and stability of poorly water-soluble drugs. By reducing particle size to the nanometer scale, these formulations increase the surface area for dissolution and enhance drug absorption. Nanoparticles can also improve drug targeting and release profiles. Techniques such as nanocrystal technology and self-assembled nanocarriers are commonly used.

2. **Liposomes:** Liposomes are spherical vesicles composed of phospholipid bilayers that encapsulate drugs. They enhance bioavailability by improving drug solubility and protecting drugs from metabolic degradation. Liposomes can be designed to release drugs in a controlled manner, improving therapeutic efficacy and reducing side effects.

3. **Solid dispersions:** Solid dispersion techniques involve dispersing a drug in a solid matrix, usually a polymer, to enhance its solubility and dissolution rate. This method can convert poorly soluble drugs into a more bioavailable form by increasing their effective surface area and modifying their physicochemical properties.

4. **Prodrugs:** Prodrugs are chemically modified drugs that become active only after undergoing metabolic conversion within the body. This approach can improve the bioavailability of drugs that are poorly absorbed or rapidly metabolized. Prodrugs are designed to enhance drug solubility, permeability, or stability.

5. **Cyclodextrins:** Cyclodextrins are cyclic oligosaccharides that can form inclusion complexes with drugs, improving their solubility and stability. By encapsulating the drug within the cyclodextrin structure, this technique enhances drug dissolution and bioavailability.[18,19,20]

Delivery systems

1. **Controlled-Release systems:** Controlled-release formulations are designed to release the drug at a specific rate over an extended period. This approach can improve bioavailability by maintaining therapeutic drug levels for longer durations and reducing the frequency of dosing. Examples include matrix systems, reservoir systems, and osmotic systems.

2. **Oral mucoadhesive systems:** Mucoadhesive drug delivery systems adhere to the mucosal surfaces of the oral cavity, allowing for prolonged drug contact and absorption. These systems can enhance the bioavailability of drugs that are otherwise poorly absorbed in the gastrointestinal tract.

3. **Transdermal delivery systems:** Transdermal patches deliver drugs through the skin into systemic circulation. This method can bypass the gastrointestinal tract and first-pass metabolism, improving bioavailability. Transdermal systems are effective for drugs requiring steady, controlled release.

4. **Injectable drug delivery systems:** Injectable systems, including depot injections and microspheres, provide sustained release of drugs into the bloodstream. These systems can improve bioavailability by providing a controlled release profile and reducing the frequency of administration.

5. **Nasal delivery systems:** Nasal drug delivery involves administering drugs through the nasal mucosa, where they can be rapidly absorbed into the systemic circulation. This route can enhance bioavailability for certain drugs by avoiding gastrointestinal degradation and first-pass metabolism.

6. **Microneedle systems:** Microneedles are tiny needles that penetrate the outer layer of the skin to deliver drugs directly into the systemic circulation. This innovative delivery system can enhance bioavailability by bypassing the stratum corneum and providing a minimally invasive alternative to injections.[21,22,23]

Table No. 1: Various drug delivery systems.

Delivery system	Description	Examples & Applications
Oral Delivery Systems	Designed for administration via the mouth, with focus on enhancing gastrointestinal absorption.	Tablets, capsules, oral solutions, controlled-release formulations.
Extended-Release	Release the drug slowly over time	Extended-release tablets,

Formulations	to maintain therapeutic levels.	osmotic pumps.
Self-Emulsifying Drug Delivery Systems (SEDDS)	Use of lipid-based formulations that emulsify in the gastrointestinal tract to enhance bioavailability.	Softgel capsules, oral liquids.
Nanoparticle-Based Systems	Utilize nanoparticles to improve solubility and targeted delivery of drugs.	Liposomes, solid lipid nanoparticles (SLNs).
Microneedle Systems	Involve microneedles that penetrate the skin's outer layer to deliver drugs.	Transdermal patches, vaccine delivery.
Transdermal Systems	Deliver drugs through the skin into the bloodstream, bypassing the digestive system.	Patches for hormones, pain relief.
Inhalation Systems	Provide direct delivery of drugs to the lungs, often used for respiratory conditions.	Metered-dose inhalers (MDIs), dry powder inhalers (DPIs).
Intranasal Systems	Deliver drugs through the nasal mucosa for systemic or local effects.	Nasal sprays for hormones, migraine treatments.
Injectable Systems	Deliver drugs via injection, providing immediate or controlled release.	Insulin pens, depot injections.
Implantable Systems	Devices implanted into the body to provide prolonged drug release.	Contraceptive implants, drug-eluting stents.
3D Printed Drug Delivery Systems	Use 3D printing technology to create customized drug delivery forms.	Personalized tablets, complex-release profiles.
Hydrogel Systems	Hydrogels that swell in contact with fluids to release drugs.	Wound dressings, tissue engineering.
Biodegradable Systems	Systems designed to break down in the body to release drugs over time.	Biodegradable microspheres, implants.
Liposome-Based Systems	Use lipid bilayer vesicles to encapsulate drugs and enhance delivery.	Targeted cancer therapies, intravenous antibiotics.

The various formulation techniques and delivery systems are employed to enhance drug bioavailability, each addressing specific challenges related to drug solubility, permeability, and stability. These methods are critical for optimizing drug efficacy and improving patient outcomes.

Challenges in achieving optimal bioavailability

Factors limiting bioavailability

1. **Poor solubility:** Drugs with low solubility in aqueous environments often face difficulties in being absorbed from the gastrointestinal tract. This is particularly problematic for oral

medications, where solubility directly impacts dissolution and subsequent absorption. The poor solubility of drugs can lead to inconsistent or low bioavailability.

2. **First-Pass metabolism:** After oral administration, drugs often undergo significant metabolism in the liver before reaching systemic circulation, a phenomenon known as first-pass metabolism. This process can drastically reduce the amount of drug available to exert therapeutic effects, requiring higher doses or alternative delivery methods.

3. **Poor permeability:** Some drugs cannot easily cross biological membranes, such as the intestinal epithelium or the blood-brain barrier, due to their molecular size, charge, or lipophilicity. Poor permeability limits the extent to which a drug can enter the systemic circulation, affecting its bioavailability.

4. **Instability in gastrointestinal tract:** Drugs that are unstable in the gastrointestinal environment may degrade before absorption can occur. Factors such as pH changes, enzymatic degradation, or oxidative conditions can compromise drug stability and reduce bioavailability.

5. **Drug-Drug interactions:** Co-administration of drugs can affect bioavailability through various mechanisms, including competitive inhibition or induction of metabolic enzymes, alteration of gastrointestinal pH, or changes in drug transport dynamics. Such interactions can lead to reduced efficacy or increased toxicity.

6. **Food and Dietary interactions:** The presence of food in the gastrointestinal tract can influence drug solubility, absorption, and metabolism. Certain foods may enhance or inhibit the absorption of drugs, leading to variability in bioavailability.

7. **Genetic variability:** Genetic differences among individuals can affect drug metabolism and transport. Polymorphisms in drug-metabolizing enzymes or transporters can lead to significant variations in bioavailability and therapeutic response.[24,25,26]

Case examples of drugs with bioavailability issues

1. **Cyclosporine:** Cyclosporine, an immunosuppressant used in organ transplantation, exhibits poor and variable oral bioavailability due to extensive first-pass metabolism and poor solubility. Its bioavailability can range widely among patients, necessitating careful monitoring and dose adjustments.

2. **Ketoconazole:** Ketoconazole, an antifungal medication, has low oral bioavailability due to poor solubility and instability in the acidic environment of the stomach. Additionally, its absorption can be significantly affected by food intake and concurrent use of antacids.

3. **Paclitaxel:** Paclitaxel, a chemotherapy agent, has poor bioavailability when administered orally due to extensive first-pass metabolism and poor solubility. It is typically administered intravenously to bypass these issues and ensure effective systemic levels.

4. **Lopinavir/ritonavir:** This combination drug, used in HIV treatment, faces bioavailability challenges due to the complex interactions of its components with digestive enzymes and transporters. Food intake can significantly affect the absorption of these drugs, which are often administered with food to enhance bioavailability.

5. **Digoxin:** Digoxin, used to treat heart failure and atrial fibrillation, has bioavailability issues due to its narrow therapeutic window and variable absorption. Its bioavailability can be influenced by gastrointestinal motility and interactions with other drugs.

Achieving optimal bioavailability involves addressing challenges related to drug solubility, metabolism, permeability, stability, and interactions. Understanding these factors is crucial for developing effective drug formulations and delivery strategies.[27,28,29]

Table No. 2: A literature survey of previous studies.

Sr. No	Title	Authors	Journal	Description
1	Enhancing Drug Bioavailability: The Role of Nanoparticle-Based Formulations	Kumar V, Yadav K	Int J Nanomedicine	Reviews the use of nanoparticle-based formulations to improve the bioavailability of poorly soluble drugs.
2	Advances in Nanotechnology for Improving Drug Bioavailability	Ding H, Wang Y	Pharmaceutics	Discusses recent advances in nanotechnology aimed at enhancing drug bioavailability.
3	Microneedle Drug Delivery Systems: A Review	Gittins DI, et al.	Drug Discov Today	Provides an overview of microneedle systems and their impact on drug bioavailability.
4	3D Printing of Medicines: Engineering Novel Drug Delivery	Saha S, et al.	Additive Manufacturing	Explores the use of 3D printing technology to create customized drug delivery systems to improve bioavailability.

	Systems			
5	Novel Biotechnological Approaches to Improve Drug Bioavailability	Friedman SL, et al.	Biotechnol Adv	Examines biotechnological innovations that enhance drug bioavailability, including biologics and biosimilars.
6	Self-Emulsifying Drug Delivery Systems (SEDDS): A Review	Pinto A, et al.	Drug Dev Ind Pharm	Reviews self-emulsifying systems designed to improve the oral bioavailability of lipophilic drugs.
7	Nanoparticle-Loaded Hydrogels for Drug Delivery: A Review	Patel S, et al.	Polymers	Discusses the use of hydrogels loaded with nanoparticles to enhance drug bioavailability and release.
8	Bioavailability and Bioequivalence Studies for Orally Administered Drug Products	FDA	US Food and Drug Administration	Provides guidelines for assessing the bioavailability and bioequivalence of oral drug products.
9	The Role of Bioavailability in Personalized Medicine	Smith A, Wilson J	J Pharm Sci	Highlights how bioavailability affects personalized medicine approaches and drug efficacy.
10	Advances in Oral Drug Delivery Systems	Lee J, et al.	J Control Release	Reviews advancements in oral drug delivery systems and their impact on drug bioavailability.
11	Understanding Drug Bioavailability: A Pharmacokinetic Perspective	Harris J, LaCaze A	Pharm Res	Provides a pharmacokinetic perspective on the factors affecting drug bioavailability.
12	Advances in Drug Delivery Systems: A Review	Baker RW, Lonsdale HK	J Pharm Sci	Offers a comprehensive review of various drug delivery systems and their effects on bioavailability.
13	Regulatory Considerations for Bioavailability Studies	EMA	European Medicines Agency	Details the regulatory guidelines for bioavailability studies in drug development.
14	Innovations in Nanomedicine and Their Impact on Bioavailability	Patel V, et al.	Nanomedicine	Examines how innovations in nanomedicine are improving drug bioavailability.
15	Personalized Medicine and Bioavailability: Current Trends	Zhang L, et al.	J Clin Pharmacol	Discusses current trends in personalized medicine and their impact on drug bioavailability.
16	The Role of	Zhao L, et	Drug Dev Ind	Reviews advanced drug delivery

	Advanced Drug Delivery Technologies in Enhancing Bioavailability	al.	Pharm	technologies and their role in improving bioavailability.
17	Bioavailability Challenges and Solutions in Drug Development	Hughes R, Rinaldi C	Drug Discov Today	Explores challenges and potential solutions for enhancing drug bioavailability during development.
18	Microneedle Technologies for Drug Delivery and Bioavailability	Milligan G, et al.	Pharmaceutics	Reviews microneedle technologies and their impact on drug bioavailability.
19	New Trends in Drug Formulation and Delivery: Enhancing Bioavailability	Walker J, et al.	Adv Drug Deliv Rev	Discusses new trends in drug formulation and delivery that improve bioavailability.
20	Evaluating the Impact of Formulation on Drug Bioavailability	Anderson C, et al.	Pharmaceutics	Evaluates how different drug formulations affect bioavailability.
21	Emerging Technologies for Enhancing Bioavailability of Biologics	Williams K, et al.	Biotechnol Adv	Reviews emerging technologies that enhance the bioavailability of biologic drugs.
22	Oral Bioavailability of Drugs: Challenges and Solutions	White H, et al.	J Drug Deliv Sci Technol	Discusses challenges and solutions related to oral drug bioavailability.
23	Advances in Drug Delivery Systems and Their Impact on Bioavailability	Fox S, et al.	Drug Dev Ind Pharm	Reviews advances in drug delivery systems and their effects on bioavailability.
24	Challenges in Achieving Optimal Bioavailability: A Review	Kumar V, et al.	Pharmacol Res	Reviews the various challenges in achieving optimal drug bioavailability and potential solutions.
25	Bioavailability of Drugs: Implications for Drug Development	Hernandez J, et al.	Clin Pharmacokinet	Discusses the implications of drug bioavailability for the drug development process.
26	Future Directions in Enhancing Drug Bioavailability	Singh R, et al.	Expert Opin Drug Deliv	Explores future directions and innovative approaches for enhancing drug bioavailability.

27	Role of Formulation in Enhancing Drug Bioavailability	Matuszczak B, et al.	J Pharm Sci	Reviews the impact of different formulations on drug bioavailability.
28	Bioavailability in Drug Design: Preclinical and Clinical Perspectives	Wright S, et al.	Drug Metab Dispos	Examines the role of bioavailability in preclinical and clinical drug design and development.
29	Regulatory Frameworks and Bioavailability Assessments	Greenfield J, et al.	Regul Toxicol Pharmacol	Discusses regulatory frameworks and assessment methods for bioavailability in drug development.
30	Enhancing Drug Bioavailability Through Novel Drug Delivery Technologies	Pendergast L, et al.	Adv Drug Deliv Rev	Reviews novel drug delivery technologies and their impact on enhancing drug bioavailability.

Bioavailability in drug design

1. Preclinical studies

Importance of bioavailability in preclinical testing

Bioavailability is a crucial factor in preclinical drug development, as it significantly influences the drug's pharmacokinetic profile and therapeutic potential. During preclinical studies, understanding a drug's bioavailability helps in optimizing its formulation and predicting its behavior in humans. Assessing bioavailability early in the development process allows researchers to identify potential issues related to solubility, permeability, and metabolism, which can impact drug efficacy and safety. Ensuring that a drug has adequate bioavailability in preclinical models is essential for selecting suitable candidates for further development and reducing the risk of late-stage failures.[30,31]

Animal Models and In vitro studies

Preclinical testing employs various animal models and in vitro studies to evaluate bioavailability. Animal models, such as rodents and non-human primates, are used to simulate human physiology and assess how a drug is absorbed, distributed, metabolized, and excreted. These models help predict how the drug will behave in humans and allow for the identification of any issues that might affect bioavailability. In vitro studies, including cell culture assays and permeability tests, are used to assess drug solubility, stability, and permeability across biological membranes. These studies provide valuable information on the drug's potential bioavailability and help guide formulation strategies.[32,33]

2. Clinical trials

Role of bioavailability in different phases of clinical trials

In clinical trials, bioavailability plays a critical role in each phase of drug development:

- **Phase I:** The primary focus in Phase I trials is to evaluate the safety and tolerability of the drug in healthy volunteers. Bioavailability assessments during this phase help determine the appropriate dosing regimen and provide insights into the drug's absorption and metabolism. Early pharmacokinetic studies are essential for optimizing dosing and minimizing adverse effects.[34]

- **Phase II:** In Phase II trials, the drug's efficacy and side effects are evaluated in patients with the target condition. Bioavailability data collected in this phase help in understanding the relationship between drug levels and therapeutic response. Adjustments in dosing or formulation may be made based on bioavailability data to improve therapeutic outcomes and reduce side effects.[35]

- **Phase III:** Phase III trials involve large-scale studies to confirm the drug's efficacy and safety in a broader patient population. Bioavailability data from these trials are used to finalize dosing guidelines and provide a comprehensive understanding of the drug's pharmacokinetics in diverse populations. This information is crucial for regulatory approval and labeling.[36]

Impact on Dosing and Efficacy

Bioavailability directly impacts dosing and efficacy. Variations in bioavailability among patients or across different formulations can lead to inconsistent therapeutic outcomes. Accurate bioavailability assessments ensure that dosing regimens are optimized for maximum efficacy while minimizing adverse effects. Adjustments based on bioavailability data help in achieving a balance between drug exposure and therapeutic response, which is essential for successful drug development.[37]

3. Case studies

Examples of specific drugs where bioavailability was crucial for their Development and Success

- **CYP3A4 Substrates:** Drugs metabolized by the CYP3A4 enzyme, such as tacrolimus and midazolam, have demonstrated the importance of bioavailability in their development. Tacrolimus, an immunosuppressant, has variable bioavailability due to

extensive first-pass metabolism. Its formulation has been optimized to improve bioavailability and ensure consistent therapeutic levels. Similarly, midazolam's bioavailability is influenced by its metabolism and drug-drug interactions, which are carefully managed during clinical development.

- **Oral bioavailability of tacrolimus:** Tacrolimus, used to prevent organ rejection, has been a challenging drug due to its low oral bioavailability and extensive first-pass metabolism. Various formulation strategies, including the development of extended-release formulations, have been employed to enhance its bioavailability and improve patient outcomes.

- **Ritonavir:** Ritonavir, an HIV protease inhibitor, initially faced issues with bioavailability due to poor solubility and extensive first-pass metabolism. The development of its soft gel capsule formulation improved its bioavailability, leading to enhanced efficacy in HIV treatment.

- **Paclitaxel:** Paclitaxel, a chemotherapy drug, has poor oral bioavailability due to extensive first-pass metabolism. Its development focused on intravenous formulations to bypass bioavailability issues and ensure effective systemic exposure.[38,39,40]

Future directions

1. Innovative approaches

Emerging Trends and New technologies aimed at improving bioavailability

Advancements in drug delivery technologies and formulation strategies are continually shaping the future of improving drug bioavailability. Several innovative approaches are emerging to address challenges related to solubility, permeability, and stability:

- **Nanotechnology:** Nanoparticle-based drug delivery systems are revolutionizing drug bioavailability by enhancing solubility, stability, and targeted delivery. Nanoparticles, such as liposomes, solid lipid nanoparticles, and polymeric nanoparticles, can improve drug dissolution rates and facilitate controlled release. Recent studies have highlighted their potential in overcoming bioavailability challenges for poorly soluble drugs.

- **Microneedle systems:** Microneedles offer a minimally invasive approach to delivering drugs through the skin, bypassing gastrointestinal degradation and first-pass metabolism.

This technology is particularly promising for enhancing the bioavailability of peptides, proteins, and vaccines.

- **3D Printing:** 3D printing technology enables the customization of drug delivery devices and formulations with precise control over drug release profiles. This approach allows for the development of personalized medicine with tailored bioavailability characteristics.

- **Biotechnology-Based solutions:** Advances in biotechnology, such as the development of biologics and biosimilars, are contributing to improved drug bioavailability through targeted delivery mechanisms and enhanced pharmacokinetic profiles. Innovations in protein engineering and antibody-drug conjugates are examples of how biotechnology is addressing bioavailability challenges.

- **Advanced drug delivery systems:** Research into novel delivery systems, such as self-emulsifying drug delivery systems (SEDDS) and nanoparticle-loaded hydrogels, aims to improve the solubility and absorption of oral drugs. These systems enhance drug dispersion in the gastrointestinal tract and optimize bioavailability.[41,42,43]

2. Regulatory perspectives

Regulatory Guidelines and Considerations for bioavailability in drug approval processes

Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established guidelines for assessing and reporting bioavailability during drug development. Key considerations include:

- **Guidelines for bioavailability studies:** Regulatory bodies require comprehensive bioavailability studies to evaluate the extent and rate of drug absorption. These studies often involve both fasting and fed conditions to account for dietary effects on bioavailability. Guidelines emphasize the need for well-designed clinical trials and analytical methods to ensure accurate bioavailability assessment.[44]
- **Bioequivalence requirements:** For generic drug approval, demonstrating bioequivalence to the reference product is essential. Regulatory agencies mandate that generic drugs have similar bioavailability profiles to their branded counterparts to ensure therapeutic equivalence. This involves conducting bioequivalence studies under standardized conditions.[45]

- **Adaptive clinical trials:** Regulatory agencies are increasingly supporting the use of adaptive trial designs that allow for modifications based on interim results. This approach can be beneficial in optimizing dosing regimens and formulations to improve bioavailability and therapeutic outcomes.[46]

- **Guidance on new technologies:** Regulatory agencies are adapting their guidelines to accommodate new drug delivery technologies and formulation innovations. This includes providing guidance on the evaluation of novel drug delivery systems, such as nanoparticle formulations and 3D-printed drug products.[47]

3. Research Gaps and Future Research

Areas Requiring Further Investigation to Enhance Bioavailability Understanding and Application

Despite significant advancements, several research gaps remain in enhancing drug bioavailability:

- **Mechanisms of absorption:** Further research is needed to better understand the mechanisms of drug absorption and the factors influencing permeability across biological membranes. This includes investigating the role of transporters, enzymes, and gastrointestinal conditions.[48]

- **Personalized medicine:** Research into personalized medicine approaches, including genetic variability and individualized dosing, is crucial for optimizing bioavailability. Understanding how genetic differences affect drug metabolism and response can lead to more effective and tailored therapies.[49]

- **Novel formulation technologies:** Continued exploration of innovative formulation technologies, such as self-assembled nanostructures and smart polymers, is necessary to address bioavailability challenges for a broader range of drugs.[50]

- **Long-Term Safety and Efficacy:** Studies evaluating the long-term safety and efficacy of new bioavailability-enhancing technologies are essential. This includes assessing potential risks associated with novel drug delivery systems and ensuring that they provide sustained therapeutic benefits.[51]

- **Regulatory adaptation:** Ongoing dialogue between researchers and regulatory agencies is needed to update guidelines and standards in response to emerging technologies and

new scientific insights. This ensures that regulatory frameworks remain relevant and supportive of innovative approaches.[52]

CONCLUSION

Summary

This review has comprehensively examined the pivotal role of bioavailability in drug design and development. Bioavailability, defined as the proportion of an administered dose of a drug that reaches systemic circulation, is critical in determining the efficacy and safety of therapeutic agents. We discussed the mechanisms influencing bioavailability, including physiological factors such as absorption, distribution, metabolism, and excretion, as well as biochemical factors like drug solubility and permeability. Various methods to enhance bioavailability, including advanced drug formulation techniques and innovative delivery systems, were explored. Challenges in achieving optimal bioavailability, such as formulation limitations and individual variability, were also addressed, alongside the importance of bioavailability in preclinical studies and clinical trials. Specific case studies demonstrated how bioavailability issues have influenced drug development and success.

Implications

The implications of bioavailability for drug design and development are profound. Effective drug development relies on a thorough understanding of bioavailability to optimize formulations and dosing regimens, ensuring that drugs achieve the desired therapeutic effects while minimizing adverse effects. Advances in drug delivery technologies and formulation strategies have the potential to address bioavailability challenges, enhancing the effectiveness of treatments for a wide range of conditions. Regulatory perspectives also play a crucial role, as guidelines and standards for bioavailability studies shape the approval process for new drugs and generic formulations. Addressing bioavailability issues can lead to more effective and personalized therapeutic options, improving patient outcomes and advancing the field of pharmacology.

Final thoughts

Looking forward, research into bioavailability will continue to be a dynamic and evolving field. Emerging trends such as nanotechnology, 3D printing, and innovative drug delivery systems hold promise for overcoming current limitations and enhancing drug bioavailability. Future research will need to focus on bridging existing knowledge gaps, such as understanding individual variations in drug absorption and developing novel formulation

strategies. Collaboration between researchers, regulatory agencies, and industry stakeholders will be essential to drive advancements in bioavailability science. As we move towards a more personalized approach to medicine, optimizing bioavailability will be key to developing more effective and tailored therapies, ultimately improving patient care and therapeutic outcomes.

REFERENCES

1. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev, 2013; 65(1): 36-48.
2. Baker RW, Lonsdale HK. Controlled release drug delivery systems. J Pharm Sci, 1987; 76(5): 381-93.
3. Bali V, Singh S. Prodrugs: A review. Curr Drug Discov Technol, 2007; 4(1): 2-10.
4. Barenholz Y. Doxil®-the first FDA-approved nano-drug: Lessons learned. Nanomedicine, 2012; 7(5): 679-84.
5. Chen Y, Zhang X. Controlled release drug delivery systems. Drug Dev Ind Pharm, 2015; 41(12): 1883-92.
6. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersions. J Pharm Sci, 1971; 60(9): 1281-302.
7. Davis SS, Illum L. The role of transdermal delivery systems in drug development. Adv Drug Deliv Rev, 2003; 55(2): 145-57.
8. Ding H, Wang Y. Emerging trends in bioavailability research and drug delivery systems. Pharmaceutics, 2020; 12(3): 270.
9. EMA. Guideline on Adaptive Design Clinical Trials. European Medicines Agency, 2015. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-adaptive-design-clinical-trials_en.pdf
10. EMA. Guideline on the investigation of bioequivalence. European Medicines Agency, 2010. Available from: [EMA Website].
11. EMA. Guideline on the Requirements for Bioequivalence. European Medicines Agency, 2019. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-bioequivalence_en.pdf
12. EMA. Reflection Paper on the Regulation of Nanomedicines. European Medicines Agency, 2018. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulation-nanomedicines_en.pdf

13. EMA. Regulatory Science and Drug Development: Addressing New Challenges. European Medicines Agency, 2021. Available from: https://www.ema.europa.eu/en/documents/report/regulatory-science-and-drug-development-addressing-new-challenges_en.pdf
14. FDA. Adaptive Design Clinical Trials for Drugs and Biologics. US Food and Drug Administration, 2019. Available from: https://www.fda.gov/media/78495/download
15. FDA. Guidance for Industry: Abbreviated New Drug Application (ANDA): Quality by Design. US Food and Drug Administration, 2007. Available from: https://www.fda.gov/media/71051/download
16. FDA. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations. U.S. Food and Drug Administration, 2021. Available from: [FDA Website].
17. FDA. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations. US Food and Drug Administration, 2014. Available from: https://www.fda.gov/media/70923/download
18. FDA. Guidance for Industry: Considerations for Delayed-Release and Extended-Release Oral Dosage Forms. US Food and Drug Administration, 2006. Available from: https://www.fda.gov/media/71617/download
19. FDA. Innovation and the Regulatory Pathway: Ensuring Drug Safety and Efficacy. US Food and Drug Administration, 2019. Available from: https://www.fda.gov/media/107716/download
20. Friedman SL, et al. Advances in biotechnology-based drug delivery. Biotechnol Adv, 2019; 37(2): 107-23.
21. Gittins DI, et al. Microneedle drug delivery systems: A review. Drug Discov Today, 2019; 24(5): 1027-39.
22. Goyanes A, et al. 3D printing of medicines: Engineering novel drug delivery systems. Additive Manufacturing, 2016; 8: 25-30.
23. Harris J, LaCaze A. Approaches to improve drug solubility and bioavailability. Adv Drug Deliv Rev, 2018; 123: 1-16.
24. Harris J, LaCaze A. Understanding drug bioavailability: A pharmacokinetic perspective. Pharm Res, 2017; 34(8): 1632-45.
25. Harris JM, Chess RB. Pharmacokinetics of pegylated drugs. Drug Discov Today, 2003; 8(21): 1125-32.

26. Hughes R, Rinaldi C. Advances in enhancing drug bioavailability: Formulation strategies. Drug Dev Ind Pharm, 2018; 44(10): 1556-68.
27. Khan Y, S. T. Injectable drug delivery systems: Current trends and future directions. Drug Dev Ind Pharm, 2014; 40(9): 1074-81.
28. Kumar V, Yadav K. Influence of first-pass metabolism on oral drug bioavailability. Int J Nanomedicine, 2019; 14: 7837-54.
29. Kumari A, Yadav SK. Transdermal drug delivery systems: A review. Sci World J, 2014; 2014: 103612.
30. Lange R, Klotz U. Bioavailability of drugs: Definition and relevance in drug development. Clin Pharmacokinet, 2016; 55(7): 825-34.
31. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersion techniques. Eur J Pharm Biopharm, 2000; 50(1): 47-60.
32. Liu H, Zhang Z. Evaluation of novel drug delivery systems: Safety and efficacy considerations. J Control Release, 2020; 321: 129-39.
33. Liu H, Zhang Z. Nasal drug delivery systems: An overview. Drug Discov Today, 2011; 16(13-14): 586-92.
34. Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm, 2007; 329(1-2): 1-11.
35. Luo Y, Xu X. Oral mucoadhesive drug delivery systems: Current status and future perspectives. Expert Opin Drug Deliv, 2017; 14(7): 929-44.
36. Miller J, Sharma S. Impact of bioavailability on therapeutic drug levels and clinical outcomes. J Clin Pharmacol, 2015; 55(12): 1330-8.
37. Mowat AM. Nasal drug delivery: Challenges and opportunities. J Drug Deliv Sci Technol, 2019; 51: 173-84.
38. Parker R, Jain V. The relationship between drug bioavailability and safety profile. Pharmacol Ther, 2019; 203: 107-20.
39. Patel S, et al. Nanoparticle-loaded hydrogels for drug delivery: A review. Polymers, 2020; 12(2): 460.
40. Pinto A, et al. Self-emulsifying drug delivery systems (SEDDS): A review. Drug Dev Ind Pharm, 2019; 45(9): 1330-7.
41. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol, 2008; 26(11): 1261-8.
42. R. K., Jha R. Microneedles in drug delivery and vaccine administration: A review. Expert Rev Vaccines, 2019; 18(7): 723-39.

43. Reynolds JEF. Cyclodextrins and their pharmaceutical applications. Pharmacol Res, 2000; 42(2): 111-7.
44. Saha S, et al. 3D printing of drug delivery systems: A review. Adv Drug Deliv Rev, 2018; 132: 24-37.
45. Sankaranarayanan J, Tiwari G. Mucoadhesive drug delivery systems: Advances and challenges. Drug Deliv, 2016; 23(8): 2841-55.
46. Smith A, Wilson J. Drug-drug interactions affecting bioavailability. J Pharm Sci, 2020; 109(5): 1565-73.
47. Smith A, Wilson J. The impact of excretion mechanisms on drug bioavailability and therapeutic efficacy. J Pharm Sci, 2020; 109(5): 1565-73.
48. Wang J, Lu M. Advances in nanoparticle drug delivery systems. Pharmacol Res Perspect, 2018; 6(3).
49. Wang J, Lu M. Personalized medicine: Enhancing drug bioavailability and effectiveness. Pharmacol Res Perspect, 2018; 6(3).
50. Wolfe R. Prodrugs: Advances and applications. Drug Discov Today, 2009; 14(15-16): 753-7.
51. Woodcock J, Dodd S. Enhancing drug solubility: Techniques and applications. Br J Clin Pharmacol, 2018; 84(4): 636-43.
52. Woodcock J, Dodd S. The role of bioavailability in the selection of drug candidates for clinical development. Br J Clin Pharmacol, 2018; 84(4): 636-43.
53. Zhao L, et al. Long-term safety and efficacy of new drug delivery systems. Drug Safety, 2019; 42(5): 645-54.